You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Claims for Patent: 10,624,906


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,624,906
Title:Spironolactone aqueous compositions
Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Inventor(s): Pipho; Anthony (Winterville, NC), DeHart; Michael Paul (Winterville, NC)
Assignee: CMP Development LLC (Farmville, NC)
Application Number:16/682,477
Patent Claims: 1. A ready-to-use liquid formulation, comprising: (a) about 0.20% w/v to about 1.0% w/v of spironolactone; (b) from about 0.18% w/v to about 0.36% w/v of a xanthan gum; (c) a pharmaceutically acceptable excipient; and (d) a sufficient amount of a water vehicle; wherein the formulation has a spironolactone content of 100.+-.10% labeled content when stored for about 24-months at 25.+-.2.degree. C. and 40.+-.5% relative humidity.

2. The ready-to-use liquid formulation of claim 1, which comprises from about 0.3% w/v to about 0.8% w/v of spironolactone.

3. The ready-to-use liquid formulation of claim 2, which comprises from about 0.20% w/v to about 0.32% w/v of a xanthan gum.

4. An enclosed bottle comprising the ready-to-use liquid formulation of claim 3.

5. The ready-to-use liquid formulation of claim 1, which comprises from about 0.4% w/v to about 0.6% w/v of spironolactone.

6. The ready-to-use liquid formulation of claim 5, which comprises from about 0.20% w/v to about 0.32% w/v of a xanthan gum.

7. An enclosed bottle comprising the ready-to-use liquid formulation of claim 6.

8. The ready-to-use liquid formulation of claim 1, which comprises about 0.5% w/v of spironolactone.

9. The ready-to-use liquid formulation of claim 8, which comprises about 0.25% of a xanthan gum.

10. The ready-to-use liquid formulation of claim 9, wherein the pharmaceutically acceptable excipient is selected from the group consisting of an anti-foaming agent, a preservative, a dispersing agent, a sweetening agent, a flavoring agent, a buffer to maintain the pH of the formulation from 4.5 to 5.5, and a combination thereof.

11. The ready-to-use liquid formulation of claim 9, wherein the pharmaceutically acceptable excipient is selected from the group consisting of from 0.2% w/v to 0.6% w/v of an anti-foaming agent, from 0.125% w/v to 0.250% w/v of a preservative, from 1.8% w/v to 2.4% w/v of a dispersing agent, from 0.04% w/v to 0.6% w/v of a sweetening agent, from 0.1% w/v to 0.5% w/v of a flavoring agent, a sufficient amount of a buffer to maintain the pH of the formulation from 4.5 to 5.5, and a combination thereof.

12. The ready-to-use liquid formulation of claim 11, wherein the buffer is selected from the group consisting of an acetate buffer, an aconitate buffer, a glutarate buffer, a glutamate buffer, a malate buffer, a succinate buffer, a tartrate buffer, a citrate buffer, and a phosphate buffer.

13. The ready-to-use liquid formulation of claim 12, wherein the sufficient amount of buffer ranges from about 10 mM to about 100 mM.

14. An enclosed bottle comprising the ready-to-use liquid formulation of claim 9.

15. The bottle of claim 14, wherein the volume of said bottle is 4 oz. or 16 oz.

16. The ready-to-use liquid formulation of claim 15, wherein a uniform content amount of spironolactone of about 100% l.c. is achieved within about 10 seconds of shaking.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.